Product information
Product name | Anti-CDKN2A/p16INK4a Antibody （BL-21301） |
Immunogen | Synthetic peptide within Human CDKN2A/p16INK4a aa 100 to the C-terminus (C terminal). |
Host | Rabbit |
Reactivity | Human |
Applications | WB, IP, IHC-P, Flow Cyt, ICC/IF |
Clonality | Polyclonal |
Isotype | IgG |
Purification | Immunogen affinity purified |
Conjugate | N/A |
Applications
WB | 1/2000. Predicted molecular weight: 17 kDa. |
ICC/IF | 1/270. |
Flow Cyt | 1/270. |
IHC-P | 1/100. |
IP | 1/30. |
Properties
Formulation | Liquid solution |
Storage buffer | Liquid in PBS, pH 7.4, containing 0.02% sodium azide as preservative, 1% BSA as stablizer and 50% Glycerol. |
Storage | Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze/ thaw cycle. |
Shipped at 4°C. | Shipped at 4°C. |
Background
CDKN2A generates several transcript variants which differ in their first exons. At least three alternatively-spliced variants encoding distinct proteins proteins were reported. Two of them named p16-INK4 and p14 are sharing 50% identity. The third one -p14(ARF) is entirely unrelated. 10883-1-AP reacts with p16 specifically. P16 plays an essential role in regulating the cell cycle, and mutations in p16 increase the risk of developing various cancers, including melanoma.
